EGFR and non-small cell lung carcinoma: The findings of the present analysis revealed that first-generation EGFR-TKI combined with an anti-angiogenesis drug significantly improved the efficacy of control of brain lesions, delayed the progression of intracranial lesions, improved prognosis and prolonged the survival times of patients with EGFRm + NSCLC with BMs.